Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down Therapy

Hommes, Daniël W.; Baert, Filip; Assche, Gert Van; Caenepeel, F; Vergauwe, Philippe; Tuynman, Hans A.R.E.; Vos, Martine De; Deventer, Sander van; Stitt, Larry; Rutgeerts, Paul; Feagan, Brian; D’Haens, Geert R.

doi:10.1053/j.gastro.2005.05.064

Cited by 50 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early administration of aggressive medical therapy with biologics and/or immunomodulators has been shown to alter the natural history of CD. [12][13][14] Since biologics do not come without potential risks, 15,16 the topdown strategy should be reserved for selected patients who have a high chance of developing complications.…”

Section: Discussionmentioning

confidence: 99%

Upper gastrointestinal tract phenotype of Crohnʼs disease is associated with early surgery and further hospitalization

Chow

Sung

et al. 2009

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Upper gastrointestinal tract phenotype of Crohnʼs disease is associated with early surgery and further hospitalization

Chow

Sung

et al. 2009

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…The search for conference abstracts yielded no further relevant trials. An abstract of the study by Hommes et al 61 was identified, which is referred to in Chapter 5, Other relevant factors. This study did not meet the criterion of a population of CD patients who are resistant or intolerant to conventional treatment.…”

Section: Quantity Of Research Availablementioning

confidence: 99%

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease

Dretzke

Edlin²,

Round³

et al. 2011

Health Technol Assess

109

132

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAA systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease ii ii NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'Nationa...

show abstract

“…Estudios han sugerido que el uso precoz de infliximab (top-down), se ha relacionado con un mejor control de la inflamación, lo que se traduce en una disminución de las secuelas crónicas, como estenosis y fístulas complejas entre otros, que implican la necesidad de cirugía en los pacientes con EII [33][34][35] . El estudio SONIC demostró que en pacientes con EC vírgenes a inmunosupresores el uso combinado de infliximab y azatioprina es más efectivo en lograr la remisión libre de esteroides y la curación de la mucosa en comparación con ambos grupos de fármacos de manera separada 33 .…”

Section: Discussionunclassified

Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local

et al. 2013

View full text Add to dashboard Cite

show abstract

Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down Therapy

Cited by 50 publications

References 0 publications

Upper gastrointestinal tract phenotype of Crohnʼs disease is associated with early surgery and further hospitalization

Upper gastrointestinal tract phenotype of Crohnʼs disease is associated with early surgery and further hospitalization

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease

Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local

Contact Info

Product

Resources

About